Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019046766) END-TO-END CELL THERAPY AUTOMATION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/046766 International Application No.: PCT/US2018/049171
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
C12N 5/0783 (2010.01) ,C12M 1/00 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0783
T cells; NK cells; Progenitors of T or NK cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
M
APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
1
Apparatus for enzymology or microbiology
Applicants:
LONZA WALKERSVILLE, INC. [US/US]; 8830 Biggs Ford Road Walkersville, MD 21793, US
LONZA COLOGNE GMBH [DE/DE]; Nattermannallee 1 50829 Cologne, DE
OCTANE BIOTECH INC. [CA/CA]; 369 Dalton Avenue Kingston, Ontario K7K 6Z1, CA
Inventors:
SHI, Yaling; US
MCAFEE, Erika; US
BANDAPALLE, Samatha; US
SIEHOFF, Ann; DE
GLEISSNER, Timo; DE
O'CONNOR, Joseph; US
ABRAHAM, Eytan; US
PURPURA, Kelly; CA
TRAINOR, Nuala; CA
SMITH, Timothy; CA
Agent:
MILLS, Jeffrey, K.; US
Priority Data:
62/553,21401.09.2017US
62/670,39111.05.2018US
Title (EN) END-TO-END CELL THERAPY AUTOMATION
(FR) AUTOMATISATION DE THÉRAPIE CELLULAIRE DE BOUT EN BOUT
Abstract:
(EN) The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
(FR) La présente invention concerne un procédé automatisé de production de cellules immunitaires génétiquement modifiées, comprenant des cellules T de récepteur d'antigène chimérique (CAR T), à l'aide d'un système d'ingénierie cellulaire entièrement clos.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)